Pharmaceuticals, Biotechnology and Life Sciences
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement to divest its Chinese research and development (R&D) subsidiary Basilea Pharmaceutica China Ltd. (“BPC”), by selling BPC’s parent company BPh Investitionen Ltd. to the U.S.-based custom manufacturing organization PHT International Inc. (“PHT”).
Basilea Pharmaceutica’s analysis of the registrational phase 2 study of potential of derazantinib in the treatment of FGFR-driven tumors, also confirmed the safety profile and tolerability of the drug candidate observed in previous clinical studies.
Basilea Pharmaceutica posted preliminary revenue for the financial year 2018, which is expected to increase by 31% over 2017 to about CHF133 million (€118.37M), from the last year’s CHF101.5 million (€90.3M).
Basilea Pharmaceutica’s CEO David Veitch, will present at the 37th Annual J. P. Morgan Healthcare Conference on January 10, 2019, where he’ll describe both the progress made during 2018 and the priorities for 2019 to deliver on the key elements of Basilea’s strategy for continued value creation, the company said Friday.
Basilea Pharmaceutica and Pfizer have extended their license agreement for Basilea’s antifungal Cresemba to China and sixteen countries in Asia…
Basilea Pharmaceutica International has amended its existing license agreement for Europe, Russia, Turkey and Israel with Pfizer Inc. for Basilea’s…
Basilea Pharmaceutica said Thursday its licensing partner Pfizer recently launched the antifungal drug Cresemba (isavuconazole) in Spain. Pfizer is now commercializing…